For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are Verona Pharma plc attached:ii 2. Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights √ An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments An event changing the breakdown of voting rights Other (please specify): CHANGE TO THE NUMBER OF VOTING RIGHTS IN ISSUE, FOLLOWING THE √ RECENT SUBSCRIPTION, PLACING AND OPEN OFFER. 3. Full name of person(s) subject to the Aviva plc & its subsidiaries notification obligation: iii Registered Holder: BNY Norwich Union Nominees Limited 4,817,119* Chase (GA Group) Nominees Limited 139,178,649* 4. Full name of shareholder(s) *denotes direct interest (if different from 3.): iv Chase (GA Group) Nominees Limited 15,111,869 Chase Nominees Limited 4,440,952 Vidacos Nominees Limited 18,701,411 5. Date of the transaction and date on which the threshold is 25 March 2014 crossed or reached: v 6. Date on which issuer 27 March 2014 notified: 7. Threshold(s) that is/ 0% to 14% Change at Direct Interest Level and are crossed or reached: vi, vii 0% to 18% Change at Combined Interest Level 8. Notified details: A: Voting rights attached to shares viii, ix Class/type of Situation Resulting situation after the triggering transaction shares previous to the triggering transaction if possible using Number Number Number Number of voting % of voting rights the ISIN CODE of of of shares rights x Shares Voting Rights Direct Direct xi Indirect Direct Indirect xii Ordinary Shares NIL HELD NIL HELD 182,250,000 143,995,768 38,254,232 14.26% 3.79% GB00B06GSH43 B: Qualifying Financial Instruments Resulting situation after the triggering transaction Type of financial Expiration Exercise/ Number of voting % of voting instrument date xiii Conversion Period xiv rights that may be rights acquired if the instrument is exercised/ converted. C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi Resulting situation after the triggering transaction Type of Exercise Expiration Exercise/ Number of voting rights % of voting financial price date xvii Conversion instrument refers to rights xix, xx instrument period xviii Nominal Delta Total (A+B+C) Number of voting rights Percentage of voting rights 182,250,000 18.05% 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:- Aviva Investors Global Services Limited: Aviva plc (Parent Company) Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited) Proxy Voting: 10. Name of the proxy holder: See Section 4 11. Number of voting rights proxy holder will cease to hold: 12. Date on which proxy holder will cease to hold voting rights: 13. Additional Figures are based on a total number of voting rights of 1,009,923,481, information: as per the Company's Result of General Meeting Announcement of 24 March 2014. 14. Contact Neil Whittaker, Aviva plc name: 15. Contact telephone 01603 684420 number: END -0- Mar/27/2014 12:25 GMT
VERONA PHARMA PLC: Holding(s) in Company
Press spacebar to pause and continue. Press esc to stop.